Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sudan sentinel-site study of artemether + lumefantrine and dihydroartemisinin + piperaquine for uncomplicated falciparum malaria
ACTRN12617000276358Phase 4Recruiting
- Sponsor
- Federal Ministry of Health
- Start
- Dec 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether, lumefantrine, dihydroartemisinin and piperaquine in malaria and Falciparum malaria (PF) (2 arms), sponsored by Federal Ministry of Health. Primary endpoints: Percent of treatment failures and Adequate clinical and parasitological response. Started Dec 2016; status: recruiting.
02
Drugs
artemetherlumefantrinedihydroartemisininpiperaquine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12617000276358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000276358.